Petauri Acquires Bluprint Oncology, Cogency, Verascity and Blendworks from Brightly Network

August 14, 2024

Petauri, the Oak Hill Capital–backed pharmaceutical services platform, acquired four U.S.-based medical communications agencies — Bluprint Oncology, Cogency, Verascity, and Blendworks — from the Brightly Network. The additions expand Petauri Advance's oncology, hematology and rare-disease communications capabilities and increase the platform's depth in medical and commercial strategy, engagement, and education.

Buyers
Petauri, Oak Hill Capital
Targets
Bluprint Oncology, Cogency, Verascity, Blendworks
Sellers
Brightly Network
Platforms
Petauri Advance
Location
United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.